ARO-ALK7
NCT06937203
Arrowhead · Phase 1/2 · Recruiting · Enrollment 150
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part 1 and Part 2 (optional cohort): ARO-ALK7 | n/r | n/r | n/r | n/r |
| Part 1 and Part 2 (optional cohort): Placebo | n/r | n/r | n/r | n/r |
| Part:2: ARO-ALK7 + Tirzepatide | n/r | n/r | n/r | n/r |
| Part 2: Placebo + Tirzepatide | n/r | n/r | n/r | n/r |
Not shown
- Part 1 and Part 2 (optional cohort): ARO-ALK7: endpoint not reported
- Part 1 and Part 2 (optional cohort): Placebo: endpoint not reported
- Part:2: ARO-ALK7 + Tirzepatide: endpoint not reported
- Part 2: Placebo + Tirzepatide: endpoint not reported